Stay updated with breaking news from Exercise Capacity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant...
New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,Show Sustained Improvements in Clinical Efficacy Endpointsand No Treatment Interruptions for Low Ejection Fraction ...
Cytokinetics, Incorporated announced that the baseline characteristics of patients randomized in SEQUOIA-HCM , the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive...
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive
Read these unbiased VShred reviews and learn important details about the company before purchasing any of its programs 2023.